1.A result of the detection of homozygous deletion of SMN1 gene in the spinal muscular atrophy
Esukhei E ; Khandsuren B ; Erdenetuya D ; Bolormaa D ; Mandakhnar M ; Oyungerel B ; Sarantsetseg S ; Yundendash D ; Nyam-Erdene N ; Batchimeg B ; Altansukh Ts ; Munkhbayar S ; Chimeglkham B
Mongolian Medical Sciences 2024;207(1):20-29
Background:
Spinal muscular atrophy (SMA) is a degenerative neuromuscular disease that causes progressive
muscle weakness and atrophy due to the loss of the motor neurons. Approximately 95% of patients
with SMA are homozygous for the deletion of SMN1 exon 7. With an incidence of 1/10.000 and a carrier
frequency of 1/40 to 1/50, SMA is the most common genetic cause of death in infants.
Purpose:
To detect homozygous deletion of SMN1 exon 7 and to analyse the SMN1 copy number by molecular
genetic analysis.
Materials and Methods:
In this study, 3 SMA patients with SMN1 gene homozygous deletion and 17 people of their relatives were
included. Molecular genetic analysis was performed in the Central Scientific Research Laboratory of the
Institute of Medical Sciences. DNA was extracted from peripheral blood, and its purity was assessed by
spectrophotometer. Homozygous deletion of SMN1 gene was analyzed with allele-specific PCR, and
the SMN1 gene copy number was evaluated by real-time PCR.
Results:
Among the five participants diagnosed with SMA by clinical symptom and electromyographic test, three
cases were found to have homozygous deletion of exon 7 of the SMN1 gene, while two cases did not
exhibit such mutation by the allele specific PCR analysis.
The mean age of study participants was 27.76±16.07 (ranging from 8 months to 52 years).
Six of the 7 relatives of the first proband had 1 copy number of SMN1 (0.75±0.29) or were carriers
of SMA, while one had 3 copy numbers (2.99) or no deletion of SMN1 gene. Additionally, 6 of the 7
individuals of the second proband had 1 copy number of the SMN1 gene (0.72±0.14), and 1 person
had 2 copy numbers. All 3 relatives of the third proband had 1 copy number of SMN1 gene (0.96±0.37).
Conclusion
We consider that determination of SMN1 gene homozygous deletion and carrier testing
can be performed by the PCR method locally. Further, it is necessary to implement the molecular
genetic testing method into practice and to study the requirements and needs of early detection of SMA
in the newborn screening program of Mongolia.
2.A study of tissue biomarkers in gastric cancer and its precursors
Nyam-Erdene N ; Tsogzolmaa Sh ; Batchimeg B ; Nomin-Erdene D ; Tuul B ; Оyunbileg N ; Zorigoo Sh ; Ganchimeg D ; Munkhbayar S ; Baasanjav N ; Tulgaa L
Mongolian Medical Sciences 2024;209(3):21-28
Background:
Specifically, stomach cancer ranks as the fifth leading cause of cancer morbidity
and mortality worldwide. Early-stage detection significantly improves survival rates,
with over 90% of patients diagnosed at stages I and II living beyond five years. To
improve the early detection of gastric cancer, it is necessary to complement the
conventional method of endoscopic examination with biomarker analysis. We aimed
to compare biomarkers such as pepsinogen C (PGC), matrix metalloproteinase 2
(MMP2), matrix metalloproteinase 9 (MMP9), and the cell proliferation marker Ki-67
with immunohistochemical analysis.
Purpose:
A comparative study and evaluation of biomarkers for the early detection of gastric
cancer.
Materials and Methods:
The study was conducted using a retrospective cohort design. Research ethics
issues were discussed at the meeting of the Medical Ethics Control Committee of
the Ministry of Health on October 13, 2023, and permission to start the research
was obtained (Resolution No. 23/051). The information was gathered based on the
criteria for K29.3, K29.4, K31, and C1 diagnoses according to the international ICD
10 classification, and participants were selected accordingly. Proteins such as PGC,
MMP2, MMP9, and Ki-67 were examined using a tissue microarray kit and evaluated
through immunohistochemical analysis.
Results:
Negative gastric tumor markers PGC, Ki-67, MMP2 and MMP9 were evaluated
by immunohistochemical analysis. The mean PGC protein staining values were
6.20±2.61 for chronic superficial gastritis, 5.45±2.47 for atrophic gastritis, 3.61±2.0 for
metaplasia, and 3.31±1.75 for gastric cancer, with statistically significant differences
between the groups (P<0.001). The mean Ki-67 protein staining values were 0.1 ±
0.4 for chronic superficial gastritis, 0.33 ± 0.55 for atrophic gastritis, 0.09 ± 0.39 for
metaplasia, and 2.62 ± 0.78 for gastric cancer, also showing statistically significant
differences (P<0.001). The mean MMP2 and MMP9 protein staining values were
0.2±0.76 and 1.2±2.04, respectively, for chronic superficial gastritis; 0.28±0.52
and 3.28±2.82 for atrophic gastritis; 0.35±1.04 and 1.12±1.45 for metaplasia; and
1.38±2.11 and 5.29±2.51 for gastric cancer, with all differences being statistically
significant (P<0.001).
Conclusion
PGC protein, a negative tumor marker, decreases during the transition
from a gastric cancer precursor to cancer. MMP2 protein, a marker of cell migration
and metastasis, has little diagnostic value, while the expression of MMP9 and the Ki
67 are highly effective in gastric cancer. Immunohistochemical analysis of endoscopic
biopsy tissue to detect the negative tumor marker PGC, the positive marker Ki-67,
and MMP9 can be used for early detection of gastric cancer.
3.Chronic kidney disease and serum NT-proBNP level
Sodgerel B ; Anudari I ; Buyandelger J ; Pilmaa Yo ; Gantogtokh D ; Yesukhei E ; Bilguun E ; Nyam-Erdene N ; Yundendash D ; Munkhbayar S ; Bolormaa Do ; Sarangerel Ga ; Munkhzul D ; Batbold B ; Sodnomtsogt L
Mongolian Medical Sciences 2024;210(4):9-17
Background:
Serum natriuretic peptide (NT-proBNP) is a critical biomarker for diagnosing left ventricular
dysfunction. Heart failure is the leading cause of mortality in chronic kidney disease (CKD),
emphasizing the need for its early detection and prognosis.
Objective:
This study aimed to determine the serum NT-proBNP levels in participants with CKD and
establish a cut-off value for predicting heart failure.
Methods:
A descriptive cross-sectional study was conducted from April 1 to July 1,2024. This study
received approval from the Ethics Committee of the Institute of Medical Sciences (Approval
No.24/01). A total of 117 CKD patients hospitalized in the Nephrology and Endocrinology
Department of the third state hospital were enrolled based on predefined inclusion and
exclusion criteria. Data were collected using questionnaires, laboratory and heart ultrasound
test results. Serum NT-proBNP levels were measured using a rapid immunofluorescence
quantitative analyzer. Data were analyzed with SPSS 26.0.
Results:
The mean age of the 117 participants was 57.9 ± 14.7 years, with 51.3% being male. The
mean serum NT-proBNP level was 7686 ± 12149 pg/mL. Statistically significant differences
were observed in serum creatinine, sodium, calcium, CKD stage, and arterial hypertension
between genders (p<0.05). NT-proBNP levels in hemodialysis patients differed significantly
between heart failure and non-heart failure groups (p<0.05). Significant differences were
also found in hemoglobin, serum albumin, NT-proBNP levels, and CKD stages (p<0.05).
NT-proBNP correlated significantly with risk factors such as hemodialysis, diabetes, and decreased systolic blood pressure (p<0.0001). A weak inverse relationship was noted
between systolic blood pressure and NT-proBNP (R² = 0.16). The NT-proBNP cut-off value
for predicting heart failure was 3027 pg/mL, with an AUC of 61.7% (sensitivity: 74.5%,
specificity: 55%).
Conclusion
Serum NT-proBNP levels are elevated in CKD patients regardless of heart
failure. The established cut-off value for NT-proBNP in CKD patients to detect heart failure
was 3027 pg/mL, with moderate diagnostic utility (AUC = 61.7%).
4.Spinal muscular atrophy: recent achievements in epidemiology, testing and gene therapy
Sarantsetseg T ; Erdenetuya D ; Yesukhei B ; Khandsuren B ; Oyungerel B ; Bolormaa D ; Mandakhnar M ; Tuul O ; Yundendash D ; Nyam-Erdene N ; Batchimeg B ; Munkhbayar S ; Chimedlkham B ; ;
Mongolian Medical Sciences 2023;205(4):75-83
Background:
Spinal Muscular Atrophy (SMA), an autosomal recessive disorder characterized by lower motor neuron
loss, leads to progressive muscle weakness and atrophy. With a neonatal incidence ranging from
1:6000 to 1:11000, individuals affected by SMA face challenges in locomotor function. The advent
of newborn screening tests, early diagnostic techniques, and the introduction of gene therapy have,
however, shown promise in enabling the acquisition of these motor skills.
Objective:
This review article seeks to shed a light on current understandings of the epidemiology, clinical
presentations, diagnostic methods, and treatments for spinal muscular atrophy, highlighting cutting
edge approaches within the discipline.
Methods:
A thorough search was conducted on PubMed, Cochrane, National Institutes of Health, and Web
of Science databases for recent research articles concerning SMA’s incidence, prevalence, clinical
manifestations, early detection, genetic testing and contemporary gene therapy.
Results:
The prevalence of SMA stands at 1-2 cases per 100,000 population, with an incidence of approximately
8 cases per 100,000 live births. Pre-1995 studies exhibited varying prevalence rates due to using non
molecular-biological methods, small localized populations, diagnostic errors, and regional characteristics.
Diagnosis involving Multiplex ligation-dependent probe amplification (MLPA), quantitative polymerase
chain reaction (qPCR), or next-generation sequencing (NGS) analysis to confirm SMN1 and SMN2
gene status aids in identifying carriers and SMA subtypes. Countries implementing newborn screening
programs have demonstrated early SMA detection in asymptomatic newborns, contributing to reduced
mortality and disability rates. Currently, several types of gene therapy are being used in the treatment
of SMA.
Conclusion
The epidemiology of SMA varies between countries and regions. It is fully possible to confirm the
disease, identify carriers and subtypes. The inclusion of SMA in newborn early detection programs is
crucial for reducing infant mortality and disability, and several gene therapies have received approval from relevant authorities for SMA treatment. In Mongolia, it is possible to introduce tests to confirm the
disease and determine carriers and subtypes.
5.A new diagnostic biomarker in early detection of Hepatocellular Carcinoma
Batchimeg B ; Baljinnyam T ; Khulan U ; Khaliun M ; Bilguun E ; Munkhtsetseg B ; Terguunbileg B ; Chinzorig M ; Gan-Erdene B ; Bilegtsaikhan Ts ; Erkhembulgan P ; Batbold B ; Munkhbat B ; Munkhtuvshin N ; Munkhbayar S
Mongolian Medical Sciences 2021;197(3):10-16
Background and Aims:
Hepatocellular carcinoma (HCC) is a common cause of cancer related death
in Mongolia. Early diagnosis is the very important management to increase successful treatment
and survival rate. Glypican-3 (GPC3) protein is highly expressed in hepatocellular carcinoma (HCC)
tissue and in serum of HCC patients. Recent studies have been conducted and suggested as a
diagnostic biomarker for detecting HCC in the early stage. Therefore, we investigated the diagnostic
value of the serum GPC3 level and compared it to the alpha-fetoprotein (AFP) level as a diagnostic
biomarker of HCC.
Methods:
We enrolled a total of 90 participants and divided into 3 groups with HCC (30), with liver
cirrhosis (LC/30) and healthy (30) as the control group (30). GPC3 and AFP serum (sGPC-3, sAFP)
levels were measured using commercially available enzyme-linked immunosorbent assay kits. The
diagnostic accuracy was analyzed using the receiver operating characteristics (ROC) curve and
estimated sensitivity and specificity of each biomarker.
Results:
sGPC3 was significantly elevated in the HCC group as compared to liver cirrhosis and
healthy subjects (658±138.2 pg/ml, 378±25.5 pg/ml, 356.3±29 pg/ml) respectively. sGPC-3 sensitivity
was 96.6% and specificity was 100%. The area under the ROC curve (AUC) for GPC3 was 0.999
(0.996- 1.0).
In comparison, the mean of AFP was significantly higher in HCC (16.9±11.7 ng/ml) than in LC (6.7±7.6
ng/ml) and in healthy subject (3.3±2.1 ng/ml) and AFP sensitivity was 43,3 %, specificity was 95 %
with an AUC of 0.808 (0.696- 0.921).
The combination of GPC-3 with AFP achieved the highest sensitivity (97.1%) and specificity (97%).
Conclusion
Serum GPC3 has a higher sensitivity than AFP for the early diagnosis of HCC.
Combination of two markers showed greatest diagnostic accuracy.
6.The effects of Particulate matter (PМ2.5) pollutants on cancer cells in in vitro model
Baljinnyam T ; Bilguun E ; Batchimeg B ; Zolzaya D ; Lkhaasuren N ; Oyungerel G ; Munkhtsetseg B ; Khaliun M ; Khulan U ; Batkhishig M ; Uranbileg U ; Sonomdagva Ch ; Bilegtsaikhan Ts ; Munkhbayar S ; Munkhtuvshin N ; Erkhembulgan P
Mongolian Medical Sciences 2021;197(3):17-25
Introduction:
Air pollution has become one of the major problems in socio-economic and health
issues in Mongolia. Among the various hazards of particulate matter (PM) pollutants, microorganisms
in PM2.5 and PM10 are thought to be responsible for various allergies and for the spread of respiratory
diseases. Recent studies have shown that PM2.5 particles can cause chronic heart failure, heart
arrhythmias, and strokes, as well as lung damage, cirrhosis, inflammation, cancer, cardiovascular
disease, and metabolic disorders. Furthermore, some studies have concluded that PM2.5 particles
in the environment are a risk factor for gastrointestinal, liver, colon, and lung cancer as well as it
affects the growth and metastasis of various cancer cells caused by other factors. In our country, the
health effects of air pollution and the relationship between the pathogenesis of cancer research are
scarce. Therefore, the study of the effects of PM2.5 particles on cancer cell proliferation, migration
(metastasis) can provide a significant role for cancer treatment, diagnosis, and prevention.
Purpose:
Determining the effects of PM2.5 particles on cancer cell proliferation, migration (metastasis)
in in-vitro
Material and Methods:
A human liver cancer cell line (HepG2), human gastric cancer cell line (AGS)
were obtained from the central scientific research laboratory in the Institute of medical sciences.
HepG2, AGS cells were seeded at a concentration of 1*105 cells/mL in a culture flask and cultured
in RPMI-1640 medium supplemented with 10% FBS, 1% antibiotic mix (penicillin, streptomycin) in a
humidified atmosphere of 5% CO2 at 37 °C. The cytotoxic effect of PM 2.5 in AGS, HepG2 cells were
evaluated by MTT, CCK8 assays. AGS, HepG2 cells were incubated in 96 well plates for 24h then
treated with different concentrations (0, 5, 10, 25, 50 and 100 μg ) of Bayankhoshuu, Buhiin urguu,
and Zaisan samples for 24h, respectively.
Results:
Concentrations of 10, 25, and 50 μg/ml of samples collected from the Bukhiin urguu and
Zaisan in March increased HepG2 cell growth, while doses of 25, 50 μg/ml of samples collected from
Bayankhoshuu in March and December increased HepG2 cell growth. Therefore, concentrations of
25 and 50 μg/ml of samples collected from Bayankhoshuu in March increased AGS cell growth, while concentrations of 25, 100 and μg/ml of samples collected in December increased AGS cell growth.
However, no cytotoxic effect was observed in the sample collected from Zaisan in March, whereas
the PM2.5 sample enhanced AGS cell growth in dose dependent manner in December.(p <0.05)
Conclusion
High levels of heavy metals were detected in samples collected in December from
Bayankhoshuu, Bukhiin urguu and Zaisan of Ulaanbaatar. Concentration of 25 μg/ml of samples
collected from the Bukhiin urguu and Zaisan in March increased HepG2 cell growth. Concentrations
of 25 μg/ml of PM2.5 collected from three regions around Ulaanbaatar increased HepG2 and AGS
cell migration.
7.Toxicology study of Hippolytii birch (B. Hippolytii. Sukacz) leaves and flat leaved birch (B.Platyphylla. Sukacz)
Munkhbayar N ; Davaasambuu T ; Murata T ; Ariunaa Z ; Tserendulam L ; Selenge E
Mongolian Pharmacy and Pharmacology 2021;18(1):17-23
Abstract:
Numerous researches conducted in Russia, Bulgaria, Japan, and China on B.pubescens, B. pendula, B.rezniczenkoana (Litv) Schischk, B.humilis Schrank, B.mandshurica Rgl Nakai found that birch barks and leaves contain antioxidants and they have anti-cancer, anti-fungi, antibac- terial and anti-inflammatory properties, protect liver and promote bile secretion. Flat leaved birch (B.platyphylla Sukacz) cortex contains betulin and lupeol of triterpenoids and it’s leaves contain flavonoid and polyphenol compounds. The amounts of compounds found in the cortex are smaller than leaves. Specifically, the amount of flavonoid in leaves is more contained than the that of cortex and leaf buds. In any pharmacology study of new medicines, determination and evaluation of toxicity is the first priority. According to scientific evidences that birch leaves are considered to have less toxins. Not many studies have been conducted on determining toxicity of birch leaves in Mongolia. Therefore, the purpose of this research is to study the species of birches, hippolytii birch (B.hippolytii. Sukacz) and flat leaved birch (B.platyphylla. Sukacz), that were noted to have medical properties in traditional medications and identify their acute toxicity using dry extract and determine mortality dosage (LD50) on animals.
Research materials and methods:
Evaluation of the acute toxicity of birch leaves was conducted in Pharmacology laboratory of Monos group’s Drug Research Institute between June 19, 2020 and August 10. In this research, 150-204 g of WISTAR breed non-linear 44 white rats were used and 20 g of B.Hippolytii’s dry extract and 20 g of B. Platyphylla ‘s dry extract were injected.
The experiments to determine the toxicity of dry extracts of B. hippolytii and B. platyphylla (LD50) were conducted according to Litchfield and Wilcoxon’s method and subcutaneous injects were per formed in the pelvic area of the rats.
Results of determining acute toxicity level
The experiments to determine the acute toxicity level of the birch’s dry extracts followed Litchfield and Wilcoxon’s method with 2-stage. LD50 level was determined from the first stage of the research using G.N.Pirshen’s method and the toxicity level was identified using K.K.Sidorov’s toxicity categorization.
From the acute toxicity research, no-observed-adverse-effect level (NOAEL), animal daily dosage and human daily dosage (experimental) were determined. LD50 2950 mg/kg was determined as a result of acute toxicity research of B.hippolytii and B.platyphilla leaves’ dry extract.
8.Study of antidiabetic and antioxidant activities for 2 species of birch leaves
Munkhbayar N ; Ariunaa Z ; Dabaasambuu L ; Murata T ; Tserendulam L ; Selenge E
Mongolian Pharmacy and Pharmacology 2021;18(1):39-47
Abstract:
The birch leaves were used as a substitute for birch bark, buds and chaga of birch in traditional medicine because the birch leaves are considered to be less toxic. Numerous researches conducted in Russia, Bulgaria, Japan, and China on B.pubescens, B. pendula, B.Rezniczenkoana (Litv) Schischk, B.humilis Schrank, and B.mandshurica Rgl Nakai found that birch barks and leaves contain antioxidants and they have anti-cancer, anti-yeast, antibacterial, anti-inflammatory, liver protective and bile secretion induction properties. The studies conducted on animals with diseases showed that the birch leaves had anti-inflammatory properties on the gastric mucosa during acute stress, as well as anti-biliary and giardiasis. The birch leaf phytopreparations experimentations used on animals showed reduced peripheral tissue insulin resistance and lowered blood sugar. Mongolian traditional medicinal journals noted that the birch barks are used to treat inflammatory acute diseases. Therefore, this study was performed to determine the effects of two species of birch leaves on blood sugar and antioxidant activities in diabetes-induced rats.
The study materials and methods:
The study was conducted in the Pharmacology Research Laboratory of the Monos Group’s Institute of Pharmacology. 40 WISTAR, non-linear white rats weighing 150-204 g were used in the experiments. Dry extract of birch leaves of the two species (Alloxan monohydrate Tokyo Chemical Industry LTD), IGM-100 3A blood glucose meter (Blood glucose test meter, Infopia LTD, Brussels Belgium) and sugar test (Blood glucose test strip only, province, China) were used for the experiment. Lenzen’s (2008) method was used to induce Alloxan diabetes in the rats and the antioxidant properties were determined by the antioxidant activity kit (Rat Malondialchehyche Elisa KIT, cat. № EKRAT- 0266, Jilin).
Study Result:
The blood glucose level of the control group with diabetes lowered from 31.5 mmol/l to 17.1 mmol/l in 14 days. As for the B.platyphylla Sukacz group, the blood glucose level reduced to 6.3 mmol/l and the B.hippolytii. Sukacz group’s blood glucose level reduced to 6.9 mmol/l in 14 days.
The study results showed that B.hippolytii Sukacz birch leaves and B.platyphilla Sukacz birch leaves’ extracts reduced the maximum level of MDA dilution (4.8 nmol/ml) of B.hippolytii Sukacz and B.platyphilla Sukacz groups by 33.9% and 53.5% respectively. This suggests that the birch leaves had antioxidant effect.
Conclusion
B.hippolytii Sukacz birch leaves and B. platyphilla (Sukacz) birch leaves lowered the blood glucose level and had antioxidant properties on diabetes.
9.A review on medicinal plants of the genus Betula
Enkh-Amgalan P ; Munkhbayar N ; Tserendulam L ; Makhpal A ; Selenge E
Mongolian Pharmacy and Pharmacology 2021;19(2):22-30
Abstract
Trees and shrubs of the genus Betula (Betulaceae) inhabit various ecosystems in temperate and boreal climate zones of the northern hemisphere. The healing properties of Betula bark and bark extracts have been known for a long time in traditional medicine in different parts of the world. Several species of Betula have traditionally been used for the treatment of various inflammatory diseases including arthritis. The purpose of this review is to provide updated, comprehensive and categorized information on the botany, traditional uses and phytochemical research of Betula species in order to explore their therapeutic potential and evaluate future research opportunities.
10.Involvement of Vitamin D in Immune system
Baljinnyam T ; Batchimeg B ; Zolzaya D ; Ganchimeg D ; Lkhaasuren N ; Oyungerel G ; Munkhtsetseg B ; Khaliun M ; Khulan U ; Bilguun E ; Batkhishig M ; Tulgaa L ; Bilegtsaikhan Ts ; Munkhbayar S ; Munkhtuvshin N ; Munkhbat B
Mongolian Medical Sciences 2020;192(2):51-59
Research of function of vitamin D on immune system has been studying since the study revealed
that vitamin D receptor is expressed on the surface of the immune cells. 1,2-dihydroxyvitamin
D3 [1,25(OH)2D], physiologically active form, can be generated through hydroxylation of
25-hydroxyvitamin D3 [25(OH)D], inactive form of vitamin D, in a liver, connecting with specific VDR
make biological action. Vitamin D make different biological actions depends on connecting with
different immunological cells. Some studies indicated that Vitamin D plays pivotal role in antibacterial
innate immune responses through regulating reaction of the main cells as macrophages and dendritic
cells. Moreover, calcitriol, the active form of vitamin D, is connected with VDRE, modulates the innate
immune response through directly inducing expression of catelicithin and β-defensin as antimicrobial
peptides, reducing secretion of IL-1b, IL-6, TNF-a, RANKL, COX-2 as proinflammatory cytokines and
increasing production of IL-10, an anti-inflammatory cytokine. Vitamin D plays in proliferation and
differentiation of T and B cells and regulates the activities of over 500 genes. Vitamin D differently
impacts on per se stages of T cells’ proliferation. Vitamin D indirectly mitigates the differentiation from
immature B cells to plasma B cells while it directly impacts on regulation of overloaded production of
antibodies in plasma B cells. In conclusion, vitamin D modulates the innate- and adaptive immune
response through regulation on activation of APCells, proliferation and differentiation of immune cells,
secretion of some antibacterial peptides.
Result Analysis
Print
Save
E-mail